North America Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

The North America Guillain-Barre Syndrome Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030).

The US market dominated the North America Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $211,863.5 Thousands by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).

The aging population has a significant impact on GBS. It primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population continues to age, there is a natural increase in the number of people at risk for GBS, contributing to the overall burden of the disease.

Additionally, by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country’s total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals.

As per the Government of Canada, in 2023, the government announced an investment of $196.1 billion over ten years, including $46.2 billion in new funding, for provinces and territories to improve health care services for Canadians. In addition, it will invest $2.5 billion over ten years to support indigenous priorities and complementary federal support, for a total of $198.6 billion over ten years.

Free Valuable Insights: The Guillain-Barre Syndrome Market is Predict to reach USD 852.2 Million by 2030, at a CAGR of 4.6%

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• F.Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• PTC, Inc.
• AstraZeneca PLC
• Novartis AG
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Merck & Co., Inc.
• Bristol Myers Squibb Company

North America Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

• Intravenous Immunoglobulin
• Plasma Exchange
• Others

By Route Of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Guillain-Barre Syndrome Market, by Therapeutics
1.4.2 North America Guillain-Barre Syndrome Market, by Route Of Administration
1.4.3 North America Guillain-Barre Syndrome Market, by Distribution Channel
1.4.4 North America Guillain-Barre Syndrome Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. North America Guillain-Barre Syndrome Market by Therapeutics
4.1 North America Intravenous Immunoglobulin Market by Country
4.2 North America Plasma Exchange Market by Country
4.3 North America Others Market by Country

Chapter 5. North America Guillain-Barre Syndrome Market by Route Of Administration
5.1 North America Parenteral Market by Country
5.2 North America Oral Market by Country

Chapter 6. North America Guillain-Barre Syndrome Market by Distribution Channel
6.1 North America Hospital Pharmacies Market by Country
6.2 North America Retail Pharmacies Market by Country
6.3 North America Others Market by Country

Chapter 7. North America Guillain-Barre Syndrome Market by Country
7.1 US Guillain-Barre Syndrome Market
7.1.1 US Guillain-Barre Syndrome Market by Therapeutics
7.1.2 US Guillain-Barre Syndrome Market by Route Of Administration
7.1.3 US Guillain-Barre Syndrome Market by Distribution Channel
7.2 Canada Guillain-Barre Syndrome Market
7.2.1 Canada Guillain-Barre Syndrome Market by Therapeutics
7.2.2 Canada Guillain-Barre Syndrome Market by Route Of Administration
7.2.3 Canada Guillain-Barre Syndrome Market by Distribution Channel
7.3 Mexico Guillain-Barre Syndrome Market
7.3.1 Mexico Guillain-Barre Syndrome Market by Therapeutics
7.3.2 Mexico Guillain-Barre Syndrome Market by Route Of Administration
7.3.3 Mexico Guillain-Barre Syndrome Market by Distribution Channel
7.4 Rest of North America Guillain-Barre Syndrome Market
7.4.1 Rest of North America Guillain-Barre Syndrome Market by Therapeutics
7.4.2 Rest of North America Guillain-Barre Syndrome Market by Route Of Administration
7.4.3 Rest of North America Guillain-Barre Syndrome Market by Distribution Channel

Chapter 8. Company Profiles
8.1 F. Hoffmann-La Roche Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 PTC, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.6 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Takeda Pharmaceutical Company Limited
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.6 SWOT Analysis
8.10. Bristol Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis

TABLE 1 North America Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 2 North America Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 3 North America Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 4 North America Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 5 North America Intravenous Immunoglobulin Market by Country, 2019 - 2022, USD Thousands
TABLE 6 North America Intravenous Immunoglobulin Market by Country, 2023 - 2030, USD Thousands
TABLE 7 North America Plasma Exchange Market by Country, 2019 - 2022, USD Thousands
TABLE 8 North America Plasma Exchange Market by Country, 2023 - 2030, USD Thousands
TABLE 9 North America Others Market by Country, 2019 - 2022, USD Thousands
TABLE 10 North America Others Market by Country, 2023 - 2030, USD Thousands
TABLE 11 North America Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 12 North America Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 13 North America Parenteral Market by Country, 2019 - 2022, USD Thousands
TABLE 14 North America Parenteral Market by Country, 2023 - 2030, USD Thousands
TABLE 15 North America Oral Market by Country, 2019 - 2022, USD Thousands
TABLE 16 North America Oral Market by Country, 2023 - 2030, USD Thousands
TABLE 17 North America Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 18 North America Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 19 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 20 North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 21 North America Retail Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 22 North America Retail Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 23 North America Others Market by Country, 2019 - 2022, USD Thousands
TABLE 24 North America Others Market by Country, 2023 - 2030, USD Thousands
TABLE 25 North America Guillain-Barre Syndrome Market by Country, 2019 - 2022, USD Thousands
TABLE 26 North America Guillain-Barre Syndrome Market by Country, 2023 - 2030, USD Thousands
TABLE 27 US Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 28 US Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 29 US Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 30 US Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 31 US Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 32 US Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 33 US Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 34 US Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 35 Canada Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 36 Canada Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 37 Canada Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 38 Canada Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 39 Canada Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 40 Canada Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 41 Canada Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 42 Canada Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 43 Mexico Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 44 Mexico Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 45 Mexico Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 46 Mexico Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 47 Mexico Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 48 Mexico Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 49 Mexico Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 50 Mexico Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 51 Rest of North America Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 52 Rest of North America Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 53 Rest of North America Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 54 Rest of North America Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 55 Rest of North America Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 56 Rest of North America Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 57 Rest of North America Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 58 Rest of North America Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 59 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 60 Key Information – Pfizer, Inc.
TABLE 61 key Information – PTC, Inc.
TABLE 62 KEY INFORMATION – AstraZeneca PLC
TABLE 63 Key Information – Novartis AG
TABLE 64 Key Information – Novo Nordisk A/S
TABLE 65 Key Information – Takeda Pharmaceutical Company Limited
TABLE 66 Key Information – Bayer AG
TABLE 67 Key Information - Merck & Co., Inc.
TABLE 68 Key Information – Bristol Myers Squibb Company

List of Figures
FIG 1 Methodology for the research
FIG 2 North America Guillain-Barre Syndrome Market, 2019 - 2030, USD Thousands
FIG 3 Key Factors Impacting Guillain-Barre Syndrome Market
FIG 4 Porter’s Five Forces Analysis – Guillain-Barre Syndrome Market
FIG 5 North America Guillain-Barre Syndrome Market share by Therapeutics, 2022
FIG 6 North America Guillain-Barre Syndrome Market share by Therapeutics, 2030
FIG 7 North America Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2030, USD Thousands
FIG 8 North America Guillain-Barre Syndrome Market share by Route Of Administration, 2022
FIG 9 North America Guillain-Barre Syndrome Market share by Route Of Administration, 2030
FIG 10 North America Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2030, USD Thousands
FIG 11 North America Guillain-Barre Syndrome Market share by Distribution Channel, 2022
FIG 12 North America Guillain-Barre Syndrome Market share by Distribution Channel, 2030
FIG 13 North America Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2030, USD Thousands
FIG 14 North America Guillain-Barre Syndrome Market share by Country, 2022
FIG 15 North America Guillain-Barre Syndrome Market share by Country, 2030
FIG 16 North America Guillain-Barre Syndrome Market by Country, 2019 - 2030, USD Thousands
FIG 17 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 18 SWOT Analysis: Pfizer, Inc.
FIG 19 SWOT Analysis: PTC, Inc.
FIG 20 SWOT Analysis: AstraZeneca PLC
FIG 21 SWOT Analysis: Novartis AG
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 SWOT Analysis:Takeda Pharmaceutical Company Limited
FIG 24 Swot Analysis: Bayer AG
FIG 25 SWOT Analysis: Merck & Co., Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company